Compare AVLN & WLTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVLN | WLTH |
|---|---|---|
| Founded | N/A | 2008 |
| Country | United States | United States |
| Employees | N/A | 391 |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2026 | N/A |
| Metric | AVLN | WLTH |
|---|---|---|
| Price | $28.73 | $9.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $12.86 |
| AVG Volume (30 Days) | 258.9K | ★ 1.0M |
| Earning Date | N/A | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $10.58 |
| Revenue Next Year | N/A | $23.43 |
| P/E Ratio | ★ N/A | $10.57 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $24.90 | $7.20 |
| 52 Week High | $33.32 | $14.12 |
| Indicator | AVLN | WLTH |
|---|---|---|
| Relative Strength Index (RSI) | 43.91 | 50.46 |
| Support Level | $26.68 | $8.65 |
| Resistance Level | $29.59 | $11.28 |
| Average True Range (ATR) | 1.99 | 0.28 |
| MACD | 0.19 | 0.05 |
| Stochastic Oscillator | 61.44 | 61.73 |
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.
Wealthfront Corp is a product-driven technology company that built a financial solutions platform for digital natives. The platform is designed to address the needs of the wealth builders within these generations. Its business model is designed to optimize for clients' success. The focus on delivering fully automated services results in being one of the lowest cost producers in each category in which participate. The group generates revenue from cash management and investment advisory products. Cash management revenue is earned from fees received for the delivery of cash management services, including the cash sweep program.